Top

Published in:

Open Access 01-12-2023 | Mood Disorders | Research

Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study

Authors: Mst. Sarmin Akter, Faisal Abdullah Emon, Zabun Nahar, MMA Shalahuddin Qusar, Sardar Mohammad Ashraful Islam, Mohammad Shahriar, Mohiuddin Ahmed Bhuiyan, Md. Rabiul Islam

Published in: BMC Psychiatry | Issue 1/2023

Abstract

Background

Major Depressive Disorder (MDD) is a common mental ailment and is the primary reason for disability. It manifests a severe impact on moods, thoughts, and physical health. At present, this disorder has become a concern in the field of public health. Alteration of neurochemicals is thought to be involved in the pathogenesis of many psychiatric disorders. Therefore, we aimed to evaluate serum IL-3 and lipocalin-2 in MDD patients and healthy controls (HCs).

Method

We included a total of 376 participants in this study. Among them, 196 were MDD patients, and 180 were age-sex-matched HCs. MDD patients were recruited from the Psychiatry Department of Bangabandhu Sheikh Mujib Medical University (BSMMU), but the controls were from different parts of Dhaka. All study participants were evaluated by a psychiatrist using the DSM-5 criteria. To assess the severity of the depression, we used the Hamilton depression (Ham-D) rating scale. Serum IL-3 and lipocalin-2 levels were measured using commercially available enzyme-linked immune-sorbent assay kits (ELISA kits).

Results

According to this study, we observed elevated serum levels of IL-3 (1,024.73 ± 29.84 pg/mL) and reduced levels of serum lipocalin-2 (29.019 ± 2.073 ng/mL) in MDD patients compared to HCs (911.11 ± 20.55 pg/mL and 48.065 ± 3.583 ng/mL, respectively). No associations between serum levels of IL-3 and lipocalin-2 and depression severity were observed in patients.

Conclusions

According to the present findings, alterations of serum IL-3 and lipocalin might be associated with the pathogenesis of MDD. These results support that altered serum neurochemicals can serve as early risk assessment markers for depression. Further interventional studies are recommended for a better understanding of the role of IL-3 and lipocalin-2 in the pathophysiology of depression.

Nothdurfter C, Milenkovic VM, Sarubin N, et al. The cytokine IL-17A as a marker of treatment resistance in major depressive disorder? Eur J Neurosci. 2021;53(1):172–82. https://doi.org/10.1111/ejn.14636.CrossRefPubMed

Islam MR, Ali S, Karmoker JR, et al. Evaluation of serum amino acids and non-enzymatic antioxidants in drug-naïve first-episode major depressive disorder. BMC Psychiatry. 2020;20(1):333. https://doi.org/10.1186/s12888-020-02738-2.CrossRefPubMedPubMedCentral

Nasca C, Bigio B, Lee FS, et al. Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci. 2018;115(34):8627–32. https://doi.org/10.1073/pnas.1801609115.CrossRefPubMedPubMedCentral

Cheng P, Wang L, Xu L, et al. Factors related to the length of stay for major depressive disorder patients in China: a real-world retrospective study. Front Public Health. 2022;10:892133. https://doi.org/10.3389/fpubh.2022.892133.CrossRefPubMedPubMedCentral

Nie LJ, Liang J, Shan F et al. L-Carnitine and Acetyl-L-Carnitine: Potential Novel Biomarkers for Major Depressive Disorder. Frontiers in Psychiatry. 2021;12. Accessed March 1, 2023. https://www.frontiersin.org/articles/https://doi.org/10.3389/fpsyt.2021.671151.

Liu Q, He H, Yang J, Feng X, Zhao F, Lyu J. Changes in the global burden of depression from 1990 to 2017: findings from the Global Burden of Disease study. J Psychiatr Res. 2020;126:134–40. https://doi.org/10.1016/j.jpsychires.2019.08.002.CrossRefPubMed

Roohi E, Jaafari N, Hashemian F. On inflammatory hypothesis of depression: what is the role of IL-6 in the middle of the chaos? J Neuroinflamm. 2021;18(1):45. https://doi.org/10.1186/s12974-021-02100-7.CrossRef

Ting EYC, Yang AC, Tsai SJ. Role of Interleukin-6 in depressive disorder. Int J Mol Sci. 2020;21(6):2194. https://doi.org/10.3390/ijms21062194.CrossRefPubMedPubMedCentral

Otte C, Gold SM, Penninx BW, et al. Major depressive disorder. Nat Rev Dis Primers. 2016;2(1):1–20. https://doi.org/10.1038/nrdp.2016.65.CrossRef

10.

Wang J, Wu X, Lai W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017;7(8):e017173. https://doi.org/10.1136/bmjopen-2017-017173.CrossRefPubMedPubMedCentral

11.

McIntyre RS. Implementing treatment strategies for different types of depression. J Clin Psychiatry. 2016;77(Suppl 1):9–15. https://doi.org/10.4088/jcp.14077su1c.02.CrossRefPubMed

12.

Hauenstein EJ. Depression in adolescence. J Obstet Gynecol Neonatal Nurs. 2003;32(2):239–48. https://doi.org/10.1177/0884217503252133.CrossRefPubMed

13.

Anjum S, Qusar MMAS, Shahriar M, Islam SMA, Bhuiyan MA, Islam MR. Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder. Therapeutic Adv Psychopharmacol. 2020;10:2045125320916655. https://doi.org/10.1177/2045125320916655.CrossRef

14.

Schneider B, Prvulovic D, Oertel-Knöchel V, et al. Biomarkers for major depression and its delineation from neurodegenerative disorders. Prog Neurobiol. 2011;95(4):703–17. https://doi.org/10.1016/j.pneurobio.2011.08.001.CrossRefPubMed

15.

Das R, Emon MPZ, Shahriar M, et al. Higher levels of serum IL-1β and TNF-α are associated with an increased probability of major depressive disorder. Psychiatry Res. 2021;295:113568. https://doi.org/10.1016/j.psychres.2020.113568.CrossRefPubMed

16.

Suneson K, Lindahl J, Chamli Hårsmar S, Söderberg G, Lindqvist D. Inflammatory Depression—mechanisms and non-pharmacological interventions. Int J Mol Sci. 2021;22(4):1640. https://doi.org/10.3390/ijms22041640.CrossRefPubMedPubMedCentral

17.

Li W, Ali T, He K, et al. Ibrutinib alleviates LPS-induced neuroinflammation and synaptic defects in a mouse model of depression. Brain Behav Immun. 2021;92:10–24. https://doi.org/10.1016/j.bbi.2020.11.008.CrossRefPubMed

18.

Emon MPZ, Das R, Nishuty NL, Shalahuddin Qusar MMA, Bhuiyan MA, Islam MR. Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case-control study with or without antidepressant therapy. BMC Res Notes. 2020;13(1):83. https://doi.org/10.1186/s13104-020-04952-3.CrossRefPubMedPubMedCentral

19.

Das R, Emon MPZ, Chowdhury SF, Huque S, Zahan T, Islam MR. Evaluation of serum glial cell line-derived neurotrophic factor in Bangladeshi major depressive disorder patients. Cureus. 2019;11(11):e6081. https://doi.org/10.7759/cureus.6081.CrossRefPubMedPubMedCentral

20.

Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. AJP. 1965;122(5):509–22. https://doi.org/10.1176/ajp.122.5.509.CrossRef

21.

Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46(10):1375–87. https://doi.org/10.1016/s0006-3223(99)00189-4.CrossRefPubMed

22.

Saveanu RV, Nemeroff CB. Etiology of Depression: genetic and environmental factors. Psychiatric Clin. 2012;35(1):51–71. https://doi.org/10.1016/j.psc.2011.12.001.CrossRef

23.

Kunugi H. Gut microbiota and pathophysiology of depressive disorder. ANM. 2021;77(2):11–20. https://doi.org/10.1159/000518274.CrossRef

24.

Jentsch MC, Van Buel EM, Bosker FJ, et al. Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses. Biomark Med. 2015;9(3):277–97. https://doi.org/10.2217/bmm.14.114.CrossRefPubMed

25.

Hacimusalar Y, Eşel E. Suggested biomarkers for major depressive disorder. Noro Psikiyatr Ars. 2018;55(3):280–90. https://doi.org/10.5152/npa.2017.19482.CrossRefPubMedPubMedCentral

26.

Islam MR, Islam MR, Ahmed I, et al. Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: a case-control study. SAGE Open Med. 2018;6:2050312118773953. https://doi.org/10.1177/2050312118773953.CrossRefPubMedPubMedCentral

27.

Xiu MH, Chen S, Wang F, et al. Altered interleukin-3 serum levels in drug-naïve and neuroleptic-treated Schizophrenic patients. Schizophr Res. 2008;106(2–3):369–70. https://doi.org/10.1016/j.schres.2008.09.001.CrossRefPubMed

28.

Giralt M, Carrasco J, Penkowa M, et al. Astrocyte-targeted expression of Interleukin-3 and Interferon-α causes region-specific changes in Metallothionein expression in the brain. Exp Neurol. 2001;168(2):334–46. https://doi.org/10.1006/exnr.2000.7601.CrossRefPubMed

29.

Dimitrov DH, Lee S, Yantis J, et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res. 2013;151(1):29–35. https://doi.org/10.1016/j.schres.2013.10.019.CrossRefPubMed

30.

Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in Schizophrenic patients. Prog Neuro-psychopharmacol Biol Psychiatry. 1995;19:75–83. https://doi.org/10.1016/0278-5846(94)00106-R.CrossRef

31.

Farrar W, Vinocour M, Hill J. In situ hybridization histochemistry localization of interleukin-3 mRNA in mouse brain. Blood. 1989;73(1):137–40. https://doi.org/10.1182/blood.V73.1.137.137.CrossRefPubMed

32.

Tabira T, Chui DH, Fan JP, Shirabe T, Konishi Y. Interleukin-3 and Interleukin-3 receptors in the Braina. Ann N Y Acad Sci. 1998;840(1):107–16. https://doi.org/10.1111/j.1749-6632.1998.tb09554.x.CrossRefPubMed

33.

Naudé PJW, den Boer JA, Comijs HC, et al. Sex-specific associations between Neutrophil Gelatinase-Associated Lipocalin (NGAL) and cognitive domains in late-life depression. Psychoneuroendocrinology. 2014;48:169–77. https://doi.org/10.1016/j.psyneuen.2014.06.016.CrossRefPubMed

34.

Naudé PJW, Eisel ULM, Comijs HC, et al. Neutrophil gelatinase-associated lipocalin: a novel inflammatory marker associated with late-life depression. J Psychosom Res. 2013;75(5):444–50. https://doi.org/10.1016/j.jpsychores.2013.08.023.CrossRefPubMed

35.

Gouweleeuw L, Naudé PJW, Rots M, DeJongste MJL, Eisel ULM, Schoemaker RG. The role of neutrophil gelatinase associated lipocalin (NGAL) as biological constituent linking depression and Cardiovascular Disease. Brain Behav Immun. 2015;46:23–32. https://doi.org/10.1016/j.bbi.2014.12.026.CrossRefPubMed

36.

Marijnissen RM, Naudé PJW, Comijs HC, Schoevers RA, Oude Voshaar RC. Waist circumference and Neutrophil Gelatinase-Associated Lipocalin in late-life depression. Brain Behav Immun. 2014;37:231–9. https://doi.org/10.1016/j.bbi.2013.12.021.CrossRefPubMed

37.

Song C, Wang H. Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(3):760–8. https://doi.org/10.1016/j.pnpbp.2010.06.020.CrossRefPubMed

38.

Nahar Z, Sal-Sabil N, Sohan M, Qusar MS, Islam MR. Higher serum interleukin-12 levels are associated with the pathophysiology of major depressive disorder: a case-control study results. Health Sci Rep. 2023;6(1):e1005. https://doi.org/10.1002/hsr2.1005.CrossRefPubMed

39.

Smith KM, Renshaw PF, Bilello J. The diagnosis of depression: current and emerging methods. Compr Psychiatr. 2013;54(1):1–6. https://doi.org/10.1016/j.comppsych.2012.06.006.CrossRef

40.

Himmerich H, Binder EB, Künzel HE, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-α system and HPA Axis. Biol Psychiatry. 2006;60(8):882–8. https://doi.org/10.1016/j.biopsych.2006.03.075.CrossRefPubMed

41.

Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the Central Nervous System. Int J Biol Sci. 2012;8(9):1254–66. https://doi.org/10.7150/ijbs.4679.CrossRefPubMedPubMedCentral

42.

Myint AM, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98(1):143–51. https://doi.org/10.1016/j.jad.2006.07.013.CrossRefPubMed

43.

Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(5):899–905. https://doi.org/10.1016/j.pnpbp.2006.01.029.CrossRefPubMed

44.

Audet MC, Anisman H. Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Frontiers in Cellular Neuroscience. 2013;7. Accessed March 1, 2023. https://www.frontiersin.org/articles/https://doi.org/10.3389/fncel.2013.00068.

45.

Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 2008;85(1):1–74. https://doi.org/10.1016/j.pneurobio.2008.01.004.CrossRefPubMed

46.

Islam S, Islam T, Nahar Z, et al. Altered serum adiponectin and interleukin-8 levels are associated in the pathophysiology of major depressive disorder: a case-control study. PLoS ONE. 2022;17(11):e0276619. https://doi.org/10.1371/journal.pone.0276619.CrossRefPubMedPubMedCentral

47.

Riya S, Sultana S, Daria S, et al. Evaluation of serum lysophosphatidic acid and lysophosphatidylcholine levels in major depressive disorder patients. Cureus. 2020;12(12). https://doi.org/10.7759/cureus.12388.

48.

Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–709. https://doi.org/10.1038/mp.2016.3.CrossRefPubMedPubMedCentral

49.

Wohleb ES, Franklin T, Iwata M, Duman RS. Integrating neuroimmune systems in the neurobiology of depression. Nat Rev Neurosci. 2016;17(8):497–511. https://doi.org/10.1038/nrn.2016.69.CrossRefPubMed

50.

Osimo EF, Pillinger T, Rodriguez IM, Khandaker GM, Pariante CM, Howes OD. Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain Behav Immun. 2020;87:901–9. https://doi.org/10.1016/j.bbi.2020.02.010.CrossRefPubMedPubMedCentral

51.

Xiu MH, Lin CG, Tian L, et al. Increased IL-3 serum levels in chronic patients with schizophrenia: Associated with psychopathology. Psychiatry Res. 2015;229(1):225–9. https://doi.org/10.1016/j.psychres.2015.07.029.CrossRefPubMed

52.

Hercus TR, Barry EF, Dottore M, et al. High yield production of a Soluble Human Interleukin-3 variant from E. Coli with Wild-Type Bioactivity and Improved Radiolabeling Properties. PLoS ONE. 2013;8(8):e74376. https://doi.org/10.1371/journal.pone.0074376.CrossRefPubMedPubMedCentral

53.

Han QQ, Yu J. Inflammation: a mechanism of depression? Neurosci Bull. 2014;30(3):515–23. https://doi.org/10.1007/s12264-013-1439-3.CrossRefPubMedPubMedCentral

54.

Ng A, Tam WW, Zhang MW, et al. IL-1β, IL-6, TNF- α and CRP in Elderly patients with Depression or Alzheimer’s Disease: systematic review and Meta-analysis. Sci Rep. 2018;8(1):12050. https://doi.org/10.1038/s41598-018-30487-6.CrossRefPubMedPubMedCentral

55.

Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science. 1987;238(4826):522–4. https://doi.org/10.1126/science.2821621.CrossRefPubMed

56.

Mota R, Gazal M, Acosta BA, et al. Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder. J Psychiatr Res. 2013;47(12):2011–4. https://doi.org/10.1016/j.jpsychires.2013.08.020.CrossRefPubMed

57.

Miklowitz DJ, Portnoff LC, Armstrong CC, et al. Inflammatory cytokines and nuclear factor-kappa B activation in adolescents with bipolar and major depressive disorders. Psychiatry Res. 2016;241:315–22. https://doi.org/10.1016/j.psychres.2016.04.120.CrossRefPubMedPubMedCentral

58.

Zou W, Feng R, Yang Y. Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression. PLoS ONE. 2018;13(6):e0197267. https://doi.org/10.1371/journal.pone.0197267.CrossRefPubMedPubMedCentral

59.

Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum Tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology. 2003;170(4):429–33. https://doi.org/10.1007/s00213-003-1566-z.CrossRefPubMed

60.

Nishuty NL, Khandoker MMH, Karmoker JR, et al. Evaluation of serum Interleukin-6 and C-reactive protein levels in Drug-naïve major depressive disorder patients. Cureus. 2019;11(1). https://doi.org/10.7759/cureus.3868.

61.

Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–14. https://doi.org/10.1016/j.jad.2015.04.044.CrossRefPubMed

62.

Elgellaie A, Thomas SJ, Kaelle J, Bartschi J, Larkin T. Pro-inflammatory cytokines IL-1α, IL-6 and TNF-α in major depressive disorder: sex-specific associations with psychological symptoms. Eur J Neurosci. 2023;57(11):1913–28. https://doi.org/10.1111/ejn.15992.CrossRefPubMed

63.

Shashidharamurthy R, Machiah D, Aitken JD, et al. Differential Role of Lipocalin 2 during Immune complex–mediated Acute and chronic inflammation in mice. Arthr Rhuem. 2013;65(4):1064–73. https://doi.org/10.1002/art.37840.CrossRef

64.

De la Chesnaye E, Manuel-Apolinar L, Oviedo-de Anda N, Revilla-Monsalve MC, Islas-Andrade S. [Gender differences in lipocalin 2 plasmatic levels are correlated with age and the triglyceride/high-density lipoprotein ratio in healthy individuals]. Gac Med Mex. 2016;152(5):612–7.PubMed

65.

Jaberi SA, Cohen A, D’Souza C, et al. Lipocalin-2: structure, function, distribution and role in metabolic disorders. Biomed Pharmacother. 2021;142:112002. https://doi.org/10.1016/j.biopha.2021.112002.CrossRefPubMed

66.

Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008;22(6):1416–26. https://doi.org/10.1210/me.2007-0420.CrossRefPubMedPubMedCentral

67.

Ferreira A, Pinto V, Mesquita S et al. Lipocalin-2 is involved in emotional behaviors and cognitive function. Frontiers in Cellular Neuroscience. 2013;7. Accessed August 4, 2023. https://www.frontiersin.org/articles/https://doi.org/10.3389/fncel.2013.00122.

68.

Kang SS, Ren Y, Liu CC, et al. Lipocalin-2 protects the brain during inflammatory conditions. Mol Psychiatry. 2018;23(2):344–50. https://doi.org/10.1038/mp.2016.243.CrossRefPubMed

69.

Dantzer R, O’Connor JC, Lawson MA, Kelley KW. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology. 2011;36(3):426–36. https://doi.org/10.1016/j.psyneuen.2010.09.012.CrossRefPubMed

70.

Reichenberg A, Yirmiya R, Schuld A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5):445–52. https://doi.org/10.1001/archpsyc.58.5.445.CrossRefPubMed

71.

Noto C, Ota VK, Gouvea ES, et al. Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis. Int J Neuropsychopharmacol. 2015;18(4):pyu042. https://doi.org/10.1093/ijnp/pyu042.CrossRefPubMedCentral

72.

Dahl J, Ormstad H, Aass HCD, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014;45:77–86. https://doi.org/10.1016/j.psyneuen.2014.03.019.CrossRefPubMed

Title: Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study
Authors: Mst. Sarmin Akter
Faisal Abdullah Emon
Zabun Nahar
MMA Shalahuddin Qusar
Sardar Mohammad Ashraful Islam
Mohammad Shahriar
Mohiuddin Ahmed Bhuiyan
Md. Rabiul Islam
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Mood Disorders
Affective Disorder
Cytokines
Published in: BMC Psychiatry / Issue 1/2023
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-023-05354-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Altered IL-3 and lipocalin-2 levels are associated with the pathophysiology of major depressive disorder: a case-control study

Abstract

Background

Method

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Predictive validity on clinical item-level of the HKT-R divided into clinical patient classes

Medication-free mental health treatment: a focus group study of milieu therapeutic settings

A blended module (STAIRS) to promote functional and personal recovery in patients with a major depressive disorder in remission: study protocol of a concurrent mixed methods randomized controlled trial

Low mindfulness is related to poor sleep quality from middle adolescents to emerging adults: a process model involving resilience and emotional dysfunction

Prevalence and associated factors of eating disorder symptoms in adolescents: a cross-sectional school-based study

Correlation between variants of the CREB1 and GRM7 genes and risk of depression